Holen Sie sich die Stockscreener-App
79.90
0.25%
-0.20
Handel nachbörslich:
79.00
-0.90
-1.13%
Schlusskurs vom Vortag:
$80.10
Offen:
$80.21
24-Stunden-Volumen:
1.27M
Relative Volume:
0.73
Marktkapitalisierung:
$7.47B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-33.89
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
-6.76%
1M Leistung:
-12.36%
6M Leistung:
+14.63%
1J Leistung:
+259.26%
1-Tages-Spanne:
$78.12
$80.52
1-Wochen-Bereich:
$76.87
$86.62
52-Wochen-Spanne:
$21.14
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
79.90 | 7.47B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | UBS | Buy |
| 2026-10-01 | Eingeleitet | JP Morgan | Overweight |
| 2026-07-28 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - Yahoo Finance
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Nigeria
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Canada
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com India
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com UK
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com Canada
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com India
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
Spyre Therapeutics Announces Grants of Inducement Awards - manilatimes.net
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Canada
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com UK
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90 - Stock Titan
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Spyre Therapeutics (SYRE) CEO sells shares in preset plan - Stock Titan
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - finance.yahoo.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - Sahm
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade) - Seeking Alpha
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - TradingView
Stifel reiterates Spyre stock Buy rating after RA study results By Investing.com - Investing.com Nigeria
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Sale |
91.83 |
7,500 |
688,756 |
79,762 |
| CAMERON TURTLE | Director |
Oct 01 '26 |
Proposed Sale |
89.03 |
45,000 |
4,006,350 |
0 |
| King-Jones Heidy | See Remarks |
Oct 01 '26 |
Sale |
91.03 |
28,933 |
2,633,902 |
2,845 |
| HEIDY KING-JONES | Officer |
Oct 01 '26 |
Proposed Sale |
89.03 |
29,335 |
2,611,695 |
0 |
| Turtle Cameron | Chief Executive Officer |
Oct 01 '26 |
Sale |
92.01 |
15,000 |
1,380,105 |
537,540 |
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
87,262 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Option Exercise |
14.50 |
17,500 |
253,750 |
97,262 |
| SCOTT BURROWS | Officer |
Sep 30 '26 |
Proposed Sale |
89.89 |
17,500 |
1,573,157 |
0 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Sale |
89.89 |
17,500 |
1,573,075 |
79,762 |
| King-Jones Heidy | See Remarks |
Sep 02 '26 |
Sale |
90.00 |
400 |
36,000 |
2,845 |
4.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):